HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHPA Adds Pavlick, Miller In Director Posts

Executive Summary

Larisa Pavlick joins senior director of quality assurance and technical affairs, and Kirby Miller as director of federal government affairs.

You may also be interested in...



'Innovation' Meeting Shows FDA-Industry Gap On NDI Guidance Details Remains

Panel discussions and public comments during FDA public meeting show industry sees agency, as it stated in draft NDI notification guidances published in 2011 and 2016, is allowing little room for innovation through making new ingredients available for use in VMS products. FDA says immense growth of the VMS market since DSHEA passed shows numerous products available in US contain substances that haven't been notified to the FDA with proof showing they are dietary ingredients and are safe for use.

UNPA Regulatory VP: Health And Wellness Industry News Roundup

UNPA adds FDA veteran as regulatory VP; USANA names VPs; and FSMA third-party auditor certification, user fee.

USPSTF Doesn’t See Forest Of VMS Benefits For Trees Of Reducing Cancer, Heart Disease Risks

US Preventative Services Task Force concludes evidence doesn't support  recommending VMS use to prevent cancer or cardiovascular disease. Trade groups and a natural medicine expert say task force's focus is narrow and its recommendation misleading. 

Topics

Latest News
UsernamePublicRestriction

Register

RS152658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel